-
公开(公告)号：US09446059B2
公开(公告)日：2016-09-20
申请号：US14919418
申请日：2015-10-21
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Eric A. Voight , Zhi Wang , Geoff G. Zhang , Valentino J. Stella
IPC: A61K31/661 , C07F9/06 , A61K31/6615
CPC classification number: C07F9/094 , A61K31/661 , A61K31/6615 , A61K45/06 , C07B2200/13 , C07C47/277 , C07C281/02 , C07C309/24 , C07F9/06 , A61K2300/00
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
Abstract translation: 本公开内容涉及（a）卡比多巴前药，（b）药物组合和包含卡比多巴前药和/或左旋多巴前药的组合物，和（c）治疗帕金森病和相关病症的方法，包括施用卡比多巴前药和 左旋多巴前药与帕金森病患者。
-
公开(公告)号：US20160122331A1
公开(公告)日：2016-05-05
申请号：US14926727
申请日：2015-10-29
Applicant: AbbVie Inc.
Inventor： Philip R. Kym , Xueqing Wang , Xenia B. Searle , Bo Liu , Ming C. Yeung
IPC: C07D407/12 , A61K45/06 , A61K31/357
CPC classification number: C07D407/12 , A61K31/357 , A61K45/06
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts or radiolabelled forms thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and m are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
Abstract translation: 式（I）化合物及其药学上可接受的盐或放射性标记形式，其中R1，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，R12和m如说明书中所定义，是有用的 在治疗由囊性纤维化跨膜电导调节剂（CFTR）蛋白质预防或改善的病症或障碍。 描述了制备化合物的方法。 还描述了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。
-
公开(公告)号：US08772500B2
公开(公告)日：2014-07-08
申请号：US13658374
申请日：2012-10-23
Applicant: AbbVie Inc.
Inventor： Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt
IPC: C07D213/00 , C07D213/28 , C07D211/74 , C07D421/00 , C07D401/00
CPC classification number: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
Abstract: Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式（II）的TRPV3的调节剂：其中G1，X1，X2，X3，X4，X5，G2，Ra，Rb和u如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号：US08772499B2
公开(公告)日：2014-07-08
申请号：US13658355
申请日：2012-10-23
Applicant: AbbVie Inc.
Inventor： Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt , Eric A. Voight
IPC: C07D213/00 , C07D213/28 , C07D211/74 , C07D421/00 , C07D401/00
CPC classification number: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
Abstract: Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式（I）的TRPV3的调节剂，其中p为1,2,3或4，并且G1，X1，X2，X3，X4，X5，G2，Z1，Ra，Rb和u如 规格。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号：US20130172334A1
公开(公告)日：2013-07-04
申请号：US13716862
申请日：2012-12-17
Applicant: AbbVie Inc.
Inventor： Michael J. Dart , Philip R. Kym , Eric A. Voight , Anurupa Shrestha , Jerome F. Daanen , Tammie K. Jinkerson , Ryan G. Keddy , Sridhar Peddi , Arthur Gomtsyan , Michael E. Kort , Gregory A. Gfesser , Kevin R. Woller , Derek W. Nelson
IPC: C07D405/12 , A61K31/192 , C07D239/80 , C07D413/12 , A61K31/4704 , C07D491/052 , A61K31/517 , A61K31/4709 , A61K31/538 , A61K45/06 , C07D215/38
CPC classification number: C07D405/12 , A61K31/192 , A61K31/4704 , A61K31/4709 , A61K31/517 , A61K31/538 , A61K45/06 , C07D215/227 , C07D215/38 , C07D239/80 , C07D265/36 , C07D413/12 , C07D413/14 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）的化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，G，Z，A，m，n和p如说明书中所定义。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
Patent Agency Ranking
公开(公告)号：US20130158067A1
公开(公告)日：2013-06-20
申请号：US13716837
申请日：2012-12-17
Applicant: AbbVie Inc.
Inventor： Kevin R. Woller , Gregory A. Gfesser , Huaqing Liu , Jerome F. Daanen , Eric A. Voight , Irene I. Drizin , Anurupa Shrestha , Kathleen H. Mortell , Philip R. Kym , Michael E. Kort , Arthur Gomtsyan
IPC: C07D311/04 , A61K45/06 , A61K31/192 , C07D311/96 , A61K31/436 , A61K31/47 , C07C275/30 , A61K31/17 , C07C275/32 , C07D491/052 , A61K31/353 , C07D215/46
CPC classification number: C07D311/04 , A61K31/17 , A61K31/192 , A61K31/353 , A61K31/436 , A61K31/47 , A61K45/06 , C07C275/30 , C07C275/32 , C07D215/42 , C07D215/46 , C07D311/68 , C07D311/70 , C07D311/96 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，Rz，A，m，n，p，q，s和位置a和b如本说明书中所定义 。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US20250122160A1
公开(公告)日：2025-04-17
申请号：US18647757
申请日：2024-04-26
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Philip R. Kym , Jennifer M. Frost , Christos Economou , Andrew Bogdan , Stacy Fosu , Zhaoming Xiong , Spencer O. Scholz , Eric Allan Voight , Elliot P. Farney , Mark A. Matulenko , Matthew J. O'Connor , Christina Baumgartner , Qingwei Zhang , Reza Shiroodi , Jason R. Abbott , Geoff T. Halvorsen
IPC: C07D285/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/501 , C07D417/04 , C07D417/12 , C07D417/14
Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
-
公开(公告)号：US20230019236A1
公开(公告)日：2023-01-19
申请号：US17807292
申请日：2022-06-16
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Elliot P. Farney , Reza Shiroodi , Zhaoming Xiong , Qingwei Zhang , Matthew J. O'Connor , Geoff T. Halvorsen , Hongyu Zhao , Christina Baumgartner , Jennifer M. Frost , Philip R. Kym , Jason R. Abbott , Andrew Bogdan , Christos Economou , Xueqing Wang
IPC: A61K31/433 , A61K39/395 , A61P35/00 , C07D417/10 , A61K31/5377 , C07D285/06
Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
-
公开(公告)号：US11091507B2
公开(公告)日：2021-08-17
申请号：US16866400
申请日：2020-05-04
Applicant: AbbVie Inc.
Inventor： Brian P. Enright , Ye Huang , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Peter T. Mayer , Christopher P. Miller , Valentino J. Stella , Eric A. Voight
IPC: C07F9/09 , A61K31/661 , C07F9/06 , C07C281/02 , C07C309/24 , C07C47/277 , A61K31/6615 , A61K45/06
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US10851073B2
公开(公告)日：2020-12-01
申请号：US16892786
申请日：2020-06-04
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Geoff T. Halvorsen , Jennifer M. Frost , Philip R. Kym
IPC: C07D285/10
Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.043 seconds)
